KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $1.4 billion.

  • AbCellera Biologics' Liabilities and Shareholders Equity fell 2.64% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 billion, marking a year-over-year decrease of 5.10%. This contributed to the annual value of $1.4 billion for FY2024, which is 8.57% down from last year.
  • AbCellera Biologics' Liabilities and Shareholders Equity amounted to $1.4 billion in FY2024, which was down 8.57% from $1.5 billion recorded in FY2023.
  • In the past 5 years, AbCellera Biologics' Liabilities and Shareholders Equity registered a high of $1.5 billion during FY2022, and its lowest value of $1.0 billion during FY2020.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $1.5 billion (2023), whereas its average is $1.5 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 31.13% in 2021, then declined by 8.57% in 2024.
  • AbCellera Biologics' Liabilities and Shareholders Equity (Yearly) stood at $1.0 billion in 2020, then spiked by 31.13% to $1.3 billion in 2021, then climbed by 16.86% to $1.5 billion in 2022, then declined by 3.43% to $1.5 billion in 2023, then dropped by 8.57% to $1.4 billion in 2024.